FARMACIA HOSPITALARIA最新文献

{"title":"The role of digital tools and artificial intelligence in supporting antimicrobial stewardship: Study protocol for a systematic review","authors":"Carlos José Cortés Sánchez,&nbsp;Fernando Salazar González,&nbsp;José María Gómez Portolés,&nbsp;Josefina Giménez Castellanos,&nbsp;Mónica Climente Martí","doi":"10.1016/j.farma.2025.11.014","DOIUrl":"10.1016/j.farma.2025.11.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Since the post-antibiotic era, there has been significant difficulty in treating infectious diseases due to the increase in antimicrobial resistance, the scarcity of new antimicrobials, and the complexity of the healthcare system. The World Health Organization (WHO) recognized it as one of the main public health problems.</div><div>To mitigate this issue, Antimicrobial Stewardship Programs (ASPs) have been established in hospital settings and in primary care, through multidisciplinary teams with specific objectives and measurable results. However, their implementation faces multiple challenges.</div><div>Digital tools and artificial intelligence (AI) can enhance these ASPs, contributing to the discovery of new molecules, the identification of resistance patterns, and improvements in infection control and prevention.</div></div><div><h3>Objective</h3><div>To analyze the role of digital tools and AI in the interventions carried out by hospital-based ASP teams to improve established outcomes.</div></div><div><h3>Material and methods</h3><div>This protocol follows the PRISMA-P methodology and has been registered in PROSPERO (ID: <strong>CRD42024601221)</strong>. A literature search will be conducted in <em>PubMed, Scopus, and the Cochrane Library</em> (2014–2024); gray literature will subsequently be reviewed in <em>Google Scholar</em>. Articles (clinical trials, interventional and observational) involving hospitalized adult patients requiring antimicrobial treatment will be included. The risk of bias will be assessed according to the study type, and methodological quality will be evaluated using the GRADE scale. Two independent researchers will perform study selection, quality assessment, and data extraction. Discrepancies will be resolved by consensus or through the intervention of a third researcher.</div></div><div><h3>Discussion</h3><div>Previous studies highlight the role of ASPs and digital tools in antimicrobial optimization. However, the difficulty and difference in the degree of implementation have also become apparent. The heterogeneity of interventions and indicators could be a limiting factor for conducting a meta-analysis. Despite these limitations, this systematic review will provide a better understanding of the potential use of digital tools and AI in hospital-based ASPs.</div></div><div><h3>Protocol registration</h3><div>This protocol has been registered in <strong>PROSPERO</strong> with the ID: <strong>CRD42024601221.</strong></div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 273-278"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aplicación del cuestionario de autoevaluación de las Declaraciones de Basilea en 8 hospitales de América Latina","authors":"Esteban Zavaleta-Monestel,&nbsp;Arturo Villalobos-Madriz,&nbsp;Abigail Fallas-Mora,&nbsp;Ernesto Martínez-Vargas,&nbsp;Amil Munich-Calvo,&nbsp;Vania Teixeira,&nbsp;Silvestre Dalmaso-Neto,&nbsp;César Sánchez,&nbsp;Jorge Morales-Vallespín,&nbsp;Antonella Milano-Gil,&nbsp;Dadier Arroyo-Monterroza,&nbsp;Gladys Delgado-Pérez,&nbsp;Michael Stepanovic,&nbsp;Stephen Eckel,&nbsp;Marianne Ivey","doi":"10.1016/j.farma.2025.11.013","DOIUrl":"10.1016/j.farma.2025.11.013","url":null,"abstract":"<div><div>The standardization of hospital pharmacy practice remains a challenge in Latin America due to the heterogeneity of healthcare systems. The Basel Statements, developed by the International Pharmaceutical Federation, provide guidelines aimed at improving patient safety and medication management; however, their implementation across the region is inconsistent.</div></div><div><h3>Objective</h3><div>To evaluate the application of the Basel Statements Self-Assessment Questionnaire in hospitals across Latin America and identify priority areas for improvement.</div></div><div><h3>Method</h3><div>A multicenter study was conducted in eight hospitals from eight countries. A 33-item questionnaire based on the Basel Statements was electronically distributed to clinical and hospital pharmacists. A descriptive analysis was performed.</div></div><div><h3>Results</h3><div>Only 25% of hospitals reported effective integration of pharmacists into clinical decision-making. Fewer than one-third had adequate medication traceability systems. Additionally, only 37.5% reported having regulations for the use of dietary supplements. Lack of standardization in medication storage and administration was also observed, increasing the risk of medication errors.</div></div><div><h3>Conclusions</h3><div>Implementation of the Basel Statements in Latin America is heterogeneous and requires targeted interventions. Strengthening pharmacists' involvement in multidisciplinary teams, improving traceability systems, and developing stronger regulations to support the safe use of medications are essential steps to enhance patient safety in the region.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 217-224"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145985234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sterility of repackaged faricimab for intravitreal administration","authors":"Antonio Raymundo,&nbsp;Lourdes Cervera,&nbsp;Francisco Crespillo,&nbsp;Sara Esplá,&nbsp;Mariola Sirvent","doi":"10.1016/j.farma.2025.10.016","DOIUrl":"10.1016/j.farma.2025.10.016","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;New drugs such as faricimab have been developed to treat ophthalmic neovascular diseases. While these drugs increase treatment success, they also increase costs. Repackaging drugs strikes a balance between technical requirements and treatment flexibility. The aim of this study was to evaluate the microbiological stability of repackaged faricimab under controlled conditions in order its already demonstrated chemical, biological, and microbiological stability.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This was a prospective, controlled experimental study. The contents of four vials of faricimab were repackaged into 16 silicone oil-free syringes with a low dead space volume. A bubble adaptor was used to ensure the maximum efficiency from fractioning. All samples were stored at 2–8 °C. Four of the syringes were cultivated on blood and Sabouraud agar at set time points (9 days, 16 days, 23 days, and 30 days). The endpoint of the study was positive microbiological growth in any of the samples. Negative and positive controls were cultivated alongside the test samples.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;None of the 16 samples or the negative controls exhibited microbiological growth at any stage of the culturing process. All positive controls showed microbiological growth.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;When repackaged in silicone oil-free syringes, faricimab retains microbiological stability for up to 30 days when it is prepared and stored under controlled conditions.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objetivos&lt;/h3&gt;&lt;div&gt;Nuevos fármacos como faricimab se han desarrollado para las enfermedades neovasculares oftálmicas, aumentando el éxito de los tratamientos, así como sus costes. El fraccionamiento aúna el equilibrio entre los requisitos técnicos y la flexibilidad del tratamiento. El objetivo de este estudio fue evaluar la estabilidad microbiológica de faricimab fraccionado en condiciones controladas para confirmar la estabilidad química, biológica y microbiológica ya demostrada.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Métodos&lt;/h3&gt;&lt;div&gt;Se realizó un estudio experimental prospectivo y controlado. Se procedió al fraccionamiento y reacondicionamiento de cuatro viales de faricimab en 16 jeringas libres de silicona con bajo espacio muerto. Se utilizó un adaptador tipo burbuja para garantizar la máxima eficiencia del fraccionamiento. Todas las muestras se almacenaron a 2–8 °C. Cuatro jeringas se cultivaron en agar sangre y Sabouraud a los 9, 16, 23 y 30 días. Se busco el crecimiento microbiológico positivo en cualquiera de las muestras. Se utilizaron controles negativos y positivos junto las muestras.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Resultados&lt;/h3&gt;&lt;div&gt;Ninguna de las 16 muestras ni de los controles negativos mostró crecimiento microbiológico. Todos los controles positivos mostraron crecimiento microbiológico.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusiones&lt;/h3&gt;&lt;div&gt;Cuando faricimab se fracciona en jeringas sin aceite de silicona, conserva su estabilidad microbiológica hasta 30 días si ","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 265-268"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Estabilidad microbiológica de faricimab fraccionado para administración intravítrea","authors":"Antonio Raymundo,&nbsp;Lourdes Cervera,&nbsp;Francisco Crespillo,&nbsp;Sara Esplá,&nbsp;Mariola Sirvent","doi":"10.1016/j.farma.2026.02.013","DOIUrl":"10.1016/j.farma.2026.02.013","url":null,"abstract":"<div><h3>Objectives</h3><div>New drugs such as faricimab have been developed to treat ophthalmic neovascular diseases. While these drugs increase treatment success, they also increase costs. Repackaging drugs strikes a balance between technical requirements and treatment flexibility. The aim of this study was to evaluate the microbiological stability of repackaged faricimab under controlled conditions in order its already demonstrated chemical, biological, and microbiological stability.</div></div><div><h3>Methods</h3><div>This was a prospective, controlled experimental study. The contents of four vials of faricimab were repackaged into 16 silicone oil-free syringes with a low dead space volume. A bubble adaptor was used to ensure the maximum efficiency from fractioning. All samples were stored at 2–8 °C. Four of the syringes were cultivated on blood and Sabouraud agar at set time points (9 days, 16 days, 23 days, and 30 days). The endpoint of the study was positive microbiological growth in any of the samples. Negative and positive controls were cultivated alongside the test samples.</div></div><div><h3>Results</h3><div>None of the 16 samples or the negative controls exhibited microbiological growth at any stage of the culturing process. All positive controls showed microbiological growth.</div></div><div><h3>Conclusions</h3><div>When repackaged in silicone oil-free syringes, faricimab retains microbiological stability for up to 30 days when it is prepared and stored under controlled conditions.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T265-T268"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salud de Vanguardia y Farmacia Hospitalaria","authors":"Raquel Yotti","doi":"10.1016/j.farma.2026.05.003","DOIUrl":"10.1016/j.farma.2026.05.003","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 215-216"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148176889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Anticholinergic burden and its relationship with cognitive impairment in a neuropsychiatric unit","authors":"María Ruiz-Julián,&nbsp;Gerard Piñol-Ripoll","doi":"10.1016/j.farma.2026.04.006","DOIUrl":"10.1016/j.farma.2026.04.006","url":null,"abstract":"<div><h3>Background</h3><div>The use of drugs with anticholinergic activity is widespread and appears to be associated with an increased risk of cognitive impairment. We evaluated the prevalence of anticholinergic prescriptions in a neuropsychiatric unit, the anticholinergic burden and its relationship with cognitive impairment.</div></div><div><h3>Methods</h3><div>A cross-sectional observational study was conducted with 135 patients. Sociodemographic data, substance use, medical and psychiatric diagnoses, presence of cognitive impairment, and Mini-Mental State Examination (MMSE) score were collected. Anticholinergic burden was assessed using the Anticholinergic Cognitive Burden Scale (ACB) and a composite index of 14 scales, considering a high anticholinergic burden ≥<!--> <!-->3 points. Descriptive analysis, the chi-squared test, Student's <em>t</em>-test, Pearson's correlation coefficient, and multiple lineal regression models adjusted for confounding factors were performed, with <em>p</em> &lt; 0.05 for statistical significance.</div></div><div><h3>Results</h3><div>The mean number of anticholinergics per patient was 4.1 ± 1.7. According to the ACB, the mean burden was 4.8 ± 2.5. The burden was higher in patients with cognitive impairment (<em>t</em> = −<!--> <!-->2.38; <em>p</em> = 0.019). Among those exposed to high burden, 71.7% presented impairment vs. 51.7% exposed to low-moderate burden (<em>χ</em>² = 4.13; <em>p</em> = 0.042; OR = 2.36). With the 14-scale composite, the mean burden was 5.9 ± 2.8. A higher prevalence of impairment was observed in high burden (70% vs 46.7%), although this was not significant (<em>χ</em>² = 3.30; <em>p</em> = 0.069; OR = 2.36). The correlation between ACB burden and MMSE was negative and significant (<em>r</em> = −0.178; <em>p</em> = 0.039), whereas with the composite index, the correlation between total burden and MMSE was not significant (<em>r</em> = −<!--> <!-->0.092; <em>p</em> = 0.289). ACB burden was also associated with a lower MMSE score in the model adjusted for sex and age (<em>B</em> = −0.27; <em>p</em> = 0.047), losing significance after controlling for education and comorbidities (<em>B</em> = −0.24; <em>p</em> = 0.072). The anticholinergic burden estimated with multiple scales showed non-significant coefficients.</div></div><div><h3>Conclusion</h3><div>High anticholinergic consumption and burden are observed in patients with neuropsychiatric disorders, especially those with cognitive impairment. A negative correlation was detected between scores on the ACB scale and the MMSE. The findings confirm that, despite the known negative effect of anticholinergics on cognition, their prescription remains very high in populations at high risk of cognitive impairment.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T247-T252"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Adecuación de las nutriciones parenterales tricamerales a guías europeas actuales en adultos: estudio de simulación","authors":"Marta de Antonio-Cuscó,&nbsp;Agustí Albalat-Torres,&nbsp;Javier Mateu-de Antonio","doi":"10.1016/j.farma.2026.03.006","DOIUrl":"10.1016/j.farma.2026.03.006","url":null,"abstract":"<div><h3>Introduction</h3><div>The use of three-compartment parenteral nutrition bags (3CPNBs) has widely expanded due to their potential time- and cost-saving advantages compared to hospital-compounded parenteral nutrition bags (HCPNBs). However, there is limited evidence of commercial 3CPNBs to adequately meet current nutritional guidelines.</div></div><div><h3>Objectives</h3><div>This study assessed the nutritional adequacy of all commercial 3CPNBs available in Spain, according to current European guidelines, across four clinical scenarios for adult patients.</div></div><div><h3>Methods</h3><div>A simulation-based study was performed to evaluate the protein and caloric content of 3CPNBs commercially available in Spain. Four clinical scenarios were defined: early and late phases of intensive care (I1 and I2), surgical (Q), and medical (M) inpatients. Two sub-analyses were conducted: a 3CPNB-centered assessment of each formulation's theoretical adequacy for each scenario, and a patient-centered analysis involving 1,000 simulated adult patients per scenario (total: 4,000 simulations). Patients' weight was computer generated reflecting the published Spanish adult-population values (tested by the Anderson-Darling test and one-sample t-test). Nutritional requirements were calculated using ESPEN guidelines, and adequacy was defined as meeting protein and caloric targets within ±<!--> <!-->5% range.</div></div><div><h3>Results</h3><div>A total of 50 commercial 3CPNBs were identified, but 15 bags (30.0%) were excluded based on predefined criteria. Then, 35 were included in the study<strong>.</strong> While 51.4% formulations met adequacy criteria across all scenarios, 34.3% were suitable for only one, and 8.6% were unsuitable for any scenario. More than half (57.1%) failed to cover even 10% of patients in any scenario. ICU scenarios, I1 and I2, showed the lowest coverage, with only around 30% of patients with an appropriate 3CPNBs. Many weight strata showed less than 50% coverage depending on the scenario. In the 64–81,99 kg strata, around the population mean, 45.9% lacked an appropriate 3CPNBs across all scenarios.</div></div><div><h3>Conclusions</h3><div>Substantial variability existed in the adequacy of commercial 3CPNBs to ESPEN guidelines. Many formulations failed to meet the criteria or were not usable across all scenarios. Many patients with body weight around population mean had no adequate 3CPNBs. These findings supported the need for critical evaluation of 3CPNBs and still place HCPNBs as a flexible alternative, especially in complex and critically ill populations.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T232-T239"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to comments on the PSICU-ALTA protocol: first steps toward improving psychotropic prescribing after ICU discharge","authors":"Laura Doménech-Moral,&nbsp;Javier Santader-Reboreda,&nbsp;Meri Martin-Cerezuela,&nbsp;Amaia Egüés Lugea,&nbsp;Marcos Buj Vicente,&nbsp;Sofía Contreras Medina","doi":"10.1016/j.farma.2025.11.006","DOIUrl":"10.1016/j.farma.2025.11.006","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 288-289"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145821432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efectividad y seguridad en vida real de atezolizumab-carboplatino-etopósido en cáncer de pulmón microcítico de enfermedad extendida","authors":"María Belén Aznar de la Riera,&nbsp;Carmen María Valencia Soto,&nbsp;Adela García-Avello Fernández-Cueto,&nbsp;María Victoria Villacañas Palomares,&nbsp;Nerea Muñoz Unceta,&nbsp;Víctor Fernández Martínez,&nbsp;Sara Barbadillo Villanueva,&nbsp;María Rioja Carrera,&nbsp;Marta Valero Dominguez,&nbsp;Virginia Martínez Callejo","doi":"10.1016/j.farma.2025.12.004","DOIUrl":"10.1016/j.farma.2025.12.004","url":null,"abstract":"<div><h3>Objective</h3><div>The objective is to describe the real-world effectiveness and safety of atezolizumab in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage small-cell lung cancer.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study of 48 patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide between March 2022 and May 2024 at a tertiary care center. The primary endpoints were progression-free survival and overall survival, analyzed using the Kaplan–Meier method. Safety outcomes and clinical predictors of survival were also assessed using software SPSS v26.</div></div><div><h3>Results</h3><div>After a median follow-up of 7.6 months (range: 1.5–28.4), median progression-free survival was 5.8 months and median overall survival was 7.1 months. Baseline ECOG performance status (ECOG 1 and 2) and the presence of brain metastases were associated with reduced overall survival. Patients who received ≤<!--> <!-->2 cycles of maintenance atezolizumab showed inferior survival outcomes. Grade 3–4 treatment-related adverse events occurred in 60.4% (<em>n</em> = 29) of patients, with hematologic toxicity being the most frequent.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, atezolizumab in combination with carboplatin and etoposide demonstrated feasibility and a manageable safety profile in first-line treatment of extensive-stage small-cell lung cancer. Longer follow-up and larger sample sizes are warranted to confirm these findings and further define prognostic markers in clinical practice.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 225-231"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146041725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Real-world effectiveness and safety of atezolizumab-carboplatin-etoposide regimen in extensive-stage small-cell lung cancer","authors":"María Belén Aznar de la Riera,&nbsp;Carmen María Valencia Soto,&nbsp;Adela García-Avello Fernández-Cueto,&nbsp;María Victoria Villacañas Palomares,&nbsp;Nerea Muñoz Unceta,&nbsp;Víctor Fernández Martínez,&nbsp;Sara Barbadillo Villanueva,&nbsp;María Rioja Carrera,&nbsp;Marta Valero Dominguez,&nbsp;Virginia Martínez Callejo","doi":"10.1016/j.farma.2026.02.008","DOIUrl":"10.1016/j.farma.2026.02.008","url":null,"abstract":"<div><h3>Objective</h3><div>The objective is to describe the real-world effectiveness and safety of atezolizumab in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage small-cell lung cancer.</div></div><div><h3>Methods</h3><div>We conducted a retrospective observational study of 48 patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide between March 2022 and May 2024 at a tertiary care center. The primary endpoints were progression-free survival and overall survival, analyzed using the Kaplan–Meier method. Safety outcomes and clinical predictors of survival were also assessed using software SPSS v26.</div></div><div><h3>Results</h3><div>After a median follow-up of 7.6 months (range: 1.5–28.4), median progression-free survival was 5.8 months and median overall survival was 7.1 months. Baseline ECOG performance status (ECOG 1 and 2) and the presence of brain metastases were associated with reduced overall survival. Patients who received ≤<!--> <!-->2 cycles of maintenance atezolizumab showed inferior survival outcomes. Grade 3–4 treatment-related adverse events occurred in 60.4% (<em>n</em> = 29) of patients, with hematologic toxicity being the most frequent.</div></div><div><h3>Conclusions</h3><div>In this real-world cohort, atezolizumab in combination with carboplatin and etoposide demonstrated feasibility and a manageable safety profile in first-line treatment of extensive-stage small-cell lung cancer. Longer follow-up and larger sample sizes are warranted to confirm these findings and further define prognostic markers in clinical practice.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T225-T231"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}